Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress.
Samer A. Srour(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Jake A. Kushner(Baylor College of Medicine), David S. Hong(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Serdar A. Gurses(The University of Texas MD Anderson Cancer Center), Valérie Doppler(Theravectys (France)), Ying Yuan(Zhejiang Cancer Hospital), Jane Koo(Cincinnati Children's Hospital Medical Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Qi Yang(Peking University Shenzhen Hospital), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Julie Garibal(Theravectys (France)), Yali Yang(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Marie Escande(Theravectys (France)), Israa Salih(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882